Compare Crispr Therapeutics AG (CRSP) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kohl's Corporation — how do they compare? Crispr Therapeutics AG trades at $50.98 (market cap $4.97B), while Kohl's Corporation trades at $17.14 (market cap $1.86B). The key difference: Crispr Therapeutics AG is far larger — about 2.7× Kohl's Corporation's market cap, and Kohl's Corporation pays a 3.04% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KSS | |
|---|---|---|
Market Cap | $4.97B | $1.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $24.71 |
52-Week Low | $44.34 | $9.27 |
Enterprise Value | $3.32B | $7.97B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Kohl's (KSS) trades at $16.55, down 1.49% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 6.95 and P/B of 0.47. Recent earnings have consistently beaten expectations, with Q1 2026 showing early turnaround progress despite revenue declines. The company maintains a 40.52% gross margin and positive cash flow from operations of $648M in 2025, while implementing strategic changes including new leadership appointments and proprietary brand expansion.
KSS presents a value opportunity with deep discount valuations, though facing significant headwinds from declining revenues and competitive pressures. The stock's near-term trajectory depends on successful execution of turnaround initiatives and proprietary brand growth, with analyst consensus at $16.75 offering modest upside potential from current levels amid cautious market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
